TY - JOUR
T1 - TAC score better predicts survival than the BCLC following resection of hepatocellular carcinoma
AU - Lima, Henrique A.
AU - Endo, Yutaka
AU - Moazzam, Zorays
AU - Alaimo, Laura
AU - Shaikh, Chanza
AU - Munir, Muhammad M.
AU - Resende, Vivian
AU - Guglielmi, Alfredo
AU - Marques, Hugo P.
AU - Cauchy, François
AU - Lam, Vincent
AU - Poultsides, George A.
AU - Popescu, Irinel
AU - Alexandrescu, Sorin
AU - Martel, Guillaume
AU - Endo, Itaru
AU - Kitago, Minoru
AU - Shen, Feng
AU - Pawlik, Timothy M.
N1 - Publisher Copyright:
© 2022 The Authors. Journal of Surgical Oncology published by Wiley Periodicals LLC.
PY - 2023/3
Y1 - 2023/3
N2 - Background: Heterogeneity in hepatocellular carcinoma (HCC) still exists within the Barcelona clinic liver cancer (BCLC) subcategories. We developed a simple model to better discriminate and predict prognosis following resection. Methods: Patients who underwent curative-intent resection for HCC were identified from a multi-institutional database. Predictive factors of survival were identified to develop TAC (tumor burden score [TBS], alpha-fetoprotein [AFP], Child−Pugh CP]) score. Results: Among 1435 patients, median TBS was 5.1 (interquartile range [IQR]: 3.2−8.1), median AFP was 18.3 ng/ml (IQR 4.0−362.5), and 1391 (96.9%) patients were classified as CP-A. Factors associated with overall survival (OS) included TBS (low: referent; medium: HR 2.26, 95% CI: 1.73−2.96; high: HR = 3.35, 95% CI: 2.22−5.07), AFP (<400 ng/ml: referent; >400 ng/ml: HR = 1.56, 95% CI: 1.27−1.92), and CP (A: referent; B: HR = 1.81, 95% CI: 1.12−2.92) (all p < 0.05). A simplified risk score demonstrated superior concordance index, Akaike information criteria, homogeneity, and area under the curve versus BCLC (0.620 vs. 0.541; 5484.655 vs. 5536.454; 60.099 vs. 16.194; 0.62 vs. 0.55, respectively), and further stratified patients within BCLC groups relative to OS (BCLC 0, very low: 86.8%, low: 47.8%) (BCLC A, very low: 79.7%, low: 68.1%, medium: 52.5%, high: 35.6%) (BCLC B, low: 59.8%, medium: 43.7%, high: N/A). Conclusion: TAC is a simple, holistic score that consistently outperformed BCLC relative to discrimination power and prognostication following resection of HCC.
AB - Background: Heterogeneity in hepatocellular carcinoma (HCC) still exists within the Barcelona clinic liver cancer (BCLC) subcategories. We developed a simple model to better discriminate and predict prognosis following resection. Methods: Patients who underwent curative-intent resection for HCC were identified from a multi-institutional database. Predictive factors of survival were identified to develop TAC (tumor burden score [TBS], alpha-fetoprotein [AFP], Child−Pugh CP]) score. Results: Among 1435 patients, median TBS was 5.1 (interquartile range [IQR]: 3.2−8.1), median AFP was 18.3 ng/ml (IQR 4.0−362.5), and 1391 (96.9%) patients were classified as CP-A. Factors associated with overall survival (OS) included TBS (low: referent; medium: HR 2.26, 95% CI: 1.73−2.96; high: HR = 3.35, 95% CI: 2.22−5.07), AFP (<400 ng/ml: referent; >400 ng/ml: HR = 1.56, 95% CI: 1.27−1.92), and CP (A: referent; B: HR = 1.81, 95% CI: 1.12−2.92) (all p < 0.05). A simplified risk score demonstrated superior concordance index, Akaike information criteria, homogeneity, and area under the curve versus BCLC (0.620 vs. 0.541; 5484.655 vs. 5536.454; 60.099 vs. 16.194; 0.62 vs. 0.55, respectively), and further stratified patients within BCLC groups relative to OS (BCLC 0, very low: 86.8%, low: 47.8%) (BCLC A, very low: 79.7%, low: 68.1%, medium: 52.5%, high: 35.6%) (BCLC B, low: 59.8%, medium: 43.7%, high: N/A). Conclusion: TAC is a simple, holistic score that consistently outperformed BCLC relative to discrimination power and prognostication following resection of HCC.
KW - Barcelona clinic liver cancer
KW - hepatocellular carcinoma
KW - multi-institutional database
KW - prognosis
KW - resection
KW - tumor burden score
UR - http://www.scopus.com/inward/record.url?scp=85139110313&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139110313&partnerID=8YFLogxK
U2 - 10.1002/jso.27116
DO - 10.1002/jso.27116
M3 - Article
C2 - 36194039
AN - SCOPUS:85139110313
SN - 0022-4790
VL - 127
SP - 374
EP - 384
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 3
ER -